Nemaura Medical Inc. announced SFDA (Saudi Food and Drug Authority) approval of sugarBEAT®, its non-invasive wearable glucose sensor. The news comes following over a year of liaisons with the SFDA through TPMENA, the Company?s licensee in the Middle East, and is seen as a major breakthrough in product commercialisation in the territory in the Middle East, and a region with one of the world?s diabetes prevalence rates. The Company previously announced the receipt of a provisional purchase order for 1.7 million sensors and 17,000 devices from TPMENA.

The Company will now work with its licensee to commence fulfilling this purchase order. Nemaura Medical is in advanced discussions to play a pivotal role in the region with its superior sensor technology, and diabetes and metabolic health management programs. Diabetes care has been in dire need of enhancement: all countries in the region have a high prevalence of Type 2 diabetes and have projected increased rates of diabetes among their populations. The resulting healthcare costs from digital management programs are significant.

It has become imperative to national health, as well as healthcare budgets, that better, more innovative and sustainable management and prevention tools are explored to their fullest. The Company believes that SFDA approval places Nemaura Medical in an unparalleled position to gain approval across the Gulf and other regions, and to commercialise its digital programs.